GSK-1292263 | B1556

GSK-1292263 is a novel GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics.

GSK-1292263 is a novel GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics.

B1556 | GSK-1292263 DataSheet

Alternate Name/Synonyms: 3-isopropyl-5-(4-(((6-(4-(methylsulfonyl)phenyl)pyridin-3-yl)oxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1032823-75-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₂₃H₂₈N₄O₄S

Molecular Weight: 456.56

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>5 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A novel GPR119 receptor agonist

MDL Number: N/A

PubChem CID: 24996872

SMILES: CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C

InChi: InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3

InChi Key: AYJRTVVIBJSSKN-UHFFFAOYSA-N